Back

Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy

Kim, A. E.; Lou, K. W.; Giobbie-Hurder, A.; Chang, K.; Gidwani, M.; Hoebel, K.; Patel, J.; Cleveland, M.; Singh, P.; Bridge, C.; Ahmed, S. R.; Bearce, B.; Liu, W.; Fuster-Garcia, E.; Lee, E.; Lin, N. U.; Overmoyer, B.; Wen, P. Y.; Nayak, L.; Cohen, J.; Dietrich, J.; Eichler, A.; Heist, R.; Krop, I.; Lawrence, D.; Ligibel, J.; Tolaney, S.; Mayer, E.; Winer, E.; Perrino, C. M.; Summers, E. J.; Mahar, M.; Oh, K.; Shih, H.; Cahill, D.; Rosen, B. R.; Yen, Y.-F.; Kalpathy-Cramer, J.; Martinez-Lage, M.; Sullivan, R. J.; Brastianos, P. K.; Emblem, K.; Gerstner, E. R.

2023-08-28 cancer biology
10.1101/2023.08.25.554868 bioRxiv
Show abstract

Structurally and functionally aberrant vasculature is a hallmark of tumor angiogenesis and treatment resistance. Given the synergistic link between aberrant tumor vasculature and immunosuppression, we analyzed perfusion MRI for 44 patients with brain metastases (BM) undergoing treatment with pembrolizumab. To date, vascular-immune communication, or the relationship between immune checkpoint inhibitor (ICI) efficacy and vascular architecture, has not been well-characterized in human imaging studies. We found that ICI-responsive BM possessed a structurally balanced vascular makeup, which was linked to improved vascular efficiency and an immune-stimulatory microenvironment. In contrast, ICI-resistant BM were characterized by a lack of immune cell infiltration and a highly aberrant vasculature dominated by large-caliber vessels. Peri-tumor region analysis revealed early functional changes predictive of ICI resistance before radiographic evidence on conventional MRI. This study was one of the largest functional imaging studies for BM and establishes a foundation for functional studies that illuminate the mechanisms linking patterns of vascular architecture with immunosuppression, as targeting these aspects of cancer biology may serve as the basis for future combination treatments.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Cancer Research
116 papers in training set
Top 0.1%
14.4%
2
Nature Communications
4913 papers in training set
Top 28%
6.4%
3
npj Precision Oncology
48 papers in training set
Top 0.1%
6.4%
4
Clinical Cancer Research
58 papers in training set
Top 0.3%
4.9%
5
Cancers
200 papers in training set
Top 1%
4.9%
6
eLife
5422 papers in training set
Top 20%
4.3%
7
Cell Reports Medicine
140 papers in training set
Top 0.8%
4.3%
8
Neuro-Oncology Advances
24 papers in training set
Top 0.2%
3.6%
9
Scientific Reports
3102 papers in training set
Top 36%
3.6%
50% of probability mass above
10
JCI Insight
241 papers in training set
Top 1%
3.6%
11
Cell Reports
1338 papers in training set
Top 20%
2.1%
12
Neuro-Oncology
30 papers in training set
Top 0.4%
2.1%
13
Oncogene
76 papers in training set
Top 0.8%
2.1%
14
Frontiers in Oncology
95 papers in training set
Top 2%
1.9%
15
Neoplasia
22 papers in training set
Top 0.2%
1.7%
16
Nature Cancer
35 papers in training set
Top 0.7%
1.7%
17
Cancer Cell
38 papers in training set
Top 1%
1.5%
18
Communications Biology
886 papers in training set
Top 14%
1.2%
19
Theranostics
33 papers in training set
Top 0.9%
1.2%
20
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 40%
1.0%
21
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.0%
22
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.3%
0.9%
23
Angiogenesis
15 papers in training set
Top 0.2%
0.9%
24
Genome Medicine
154 papers in training set
Top 7%
0.9%
25
Journal of Cerebral Blood Flow & Metabolism
43 papers in training set
Top 0.5%
0.9%
26
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
27
PLOS ONE
4510 papers in training set
Top 64%
0.9%
28
NMR in Biomedicine
24 papers in training set
Top 0.4%
0.8%
29
Frontiers in Immunology
586 papers in training set
Top 8%
0.8%
30
British Journal of Cancer
42 papers in training set
Top 2%
0.7%